Busy week for Optimum’s clients as we head into March

Neuraxpharm launches RMS drug in Europe, calls for awareness of rare disease  In another exciting week for Optimum’s clients, Neuraxpharm kicked off proceedings with the first launch of Briumvi (ublituximab) in Europe, for treatment of relapsing multiple sclerosis.  Germany is the first country to see the launch of the drug following Neuraxpharm’s agreement with TG […]

Sector updates in February

Investment firms ARCH Venture Partners raises $3B for biotech start-ups  Earlybird Health raises €173m for health tech companies  Seroba announces the final close of its Fund IV at €123M ($134M) for early-stage life science companies  New VC fund Scion Life Sciences emerges with $310m to create independent, commercial biotechs  ORI Capital has raised $260m for […]

Optimum weekly round up – 23/02/24

It was an exciting week for Optimum’s clients with a slew of scientific data announced ahead of the ESMO Targeted Anticancer Therapies Conference 2024 – a high-profile cancer conference on the 26 February. STORM to present findings of First-in-Class METTL1 tRNA Methyltransferase Inhibitors STORM Therapeutics Ltd, the clinical stage biotechnology company discovering and developing novel […]

Optimum celebrates the International Day of Women & Girls in Science 2024

For this year’s International Day of Women and Girls in Science, Optimum is celebrating the amazing women we work with by asking them each to nominate a fellow female in life sciences who inspires them in their lives and careers. Click to discover the nominated inspirational women in life sciences! In addition to the Q&A […]

Optimum’s guide to investor pitch meetings

‘Fail to prepare, prepare to fail’ – an old adage that couldn’t be truer when it comes to maximising your valuable time and resources when attending conferences.  Here are Optimum’s top tips on how you can ensure you’re attending (a) the right events and (b) utilising the opportunities you hope for, when luck has you […]